Usher syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | Atsena Therapeutics, ProQR Therapeutics, Editas Medicine, Nacuity Pharmaceuticals

Usher syndrome emerging therapies, such as NPI-001, Ultevursen, and others, are expected to boost the Usher syndrome Market in the upcoming years.

DelveInsight has launched a new report on "Usher syndrome - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Usher syndrome, historical and forecasted epidemiology as well as the Usher syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Usher syndrome market report @ https://www.delveinsight.com/report-store/usher-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Usher syndrome Market Report:

According to DelveInsight, the total Usher Syndrome market size in the 7MM was approximately USD 77 million in 2023 and is projected to grow at a significant CAGR through the forecast period (2020-2034).
In 2023, the United States had the highest number of Usher Syndrome cases among the 7MM, with around 21,000 diagnosed individuals-a number expected to rise over time.
Key companies like Eli Lilly, Atsena Therapeutics, and Nacuity Pharmaceuticals are actively pursuing innovative treatments. However, the current market mainly depends on off-label therapies that do not target the underlying cause. Supportive interventions such as vitamin supplementation, sun protection, and visual aids remain central to patient care.
At present, Luxturna is the only approved treatment for retinal degeneration, a common feature in USH. Additionally, in January 2020, the FDA granted Rare Pediatric Disease designation to QR-421a for treating mutations in exon 13 of the USH2A gene.
In December 2024, the FDA granted Orphan Drug Designation to AAVB-081, a dual AAV8-based gene therapy targeting MYO7A mutations associated with Usher Syndrome Type 1B (USH1B). This designation provides benefits like tax credits, fee exemptions, and potential seven-year market exclusivity upon approval.
In 2023, the United States reported the highest number of Usher Syndrome prevalent cases among the 7MM, totaling approximately 21,000, with projections indicating continued growth throughout the forecast period.
Promising Usher syndrome therapies include NPI-001, Ultevursen, and others.

Usher syndrome Overview

Usher Syndrome is the leading genetic disorder associated with deaf-blindness, accounting for about 50% of cases in individuals under the age of 65. It is an inherited autosomal recessive condition that affects hearing, vision (due to retinitis pigmentosa), and balance. The syndrome presents in varying forms and onset patterns, often including balance difficulties and bilateral vestibular areflexia. Usher Syndrome is classified into three primary clinical types-Type 1, Type 2, and Type 3-each linked to mutations in different genes and further divided into subtypes.

Usher syndrome Market Outlook

Currently, **LUXTURNA (voretigene neparvovec)** is the only approved treatment for Usher Syndrome, specifically for patients with the **RPE65 mutation**, leaving most individuals without a standard therapy. These patients primarily rely on **supportive care** such as vitamin supplements, sunlight protection, and visual aids.

Only a **few companies**, including **Nacuity Pharmaceuticals** and **Laboratoires Théa**, are actively developing treatments. High-dose **vitamin A palmitate and fish oil** are commonly recommended, though evidence from clinical trials suggests **limited or no benefit**, and **vitamin E** may even interfere with vitamin A absorption.

As a result, **no effective cure or treatment** currently exists to halt or reverse disease progression in most Usher Syndrome patients.

Discover how the Usher syndrome market is rising in the coming years @ https://www.delveinsight.com/sample-request/usher-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Usher syndrome Emerging Drugs
NPI-001: Nacuity Pharmaceuticals
Ultevursen: Laboratoires Théa

Scope of the Usher syndrome Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Usher syndrome Companies: Atsena Therapeutics, ProQR Therapeutics, Editas Medicine, Nacuity Pharmaceuticals, and others
Key Usher syndrome Therapies: NPI-001, Ultevursen, and others
Usher syndrome Therapeutic Assessment: Usher syndrome current marketed and Usher syndrome emerging therapies
Usher syndrome Market Dynamics: Usher syndrome market drivers and Usher syndrome market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Usher syndrome Unmet Needs, KOL's views, Analyst's views, Usher syndrome Market Access and Reimbursement

To know what's more in our Usher syndrome report, visit https://www.delveinsight.com/report-store/usher-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Usher syndrome Market Report:
Usher syndrome market report covers a descriptive overview and comprehensive insight of the Usher syndrome Epidemiology and Usher syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Usher syndrome market report provides insights into the current and emerging therapies.
The Usher syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Usher syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Usher syndrome market.

Got queries? Click here to know more about the Usher syndrome market Landscape https://www.delveinsight.com/sample-request/usher-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Usher syndrome Patient Share (%) Overview at a Glance
5. Usher syndrome Market Overview at a Glance
6. Usher syndrome Disease Background and Overview
7. Usher syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Usher syndrome
9. Usher syndrome Current Treatment and Medical Practices
10. Unmet Needs
11. Usher syndrome Emerging Therapies
12. Usher syndrome Market Outlook
13. Country-Wise Usher syndrome Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Usher syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Usher syndrome Market Outlook 2034 https://www.delveinsight.com/report-store/usher-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Usher syndrome Pipeline Insights, DelveInsight

"Usher syndrome Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Usher syndrome market. A detailed picture of the Usher syndrome pipeline landscape is provided, which includes the disease overview and Usher syndrome treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.